. A randomized, double-blind, placebo-controlled phase 1b study to evaluate the safety, tolerability, and pharmacodynamics of an anti-amyloid-β antibody SHR-1707 in patients with mild cognitive impairment and mild Alzheimer’s disease. Alzheimer's Association, 25 December 2023 Alzheimer's Association

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. SHR-1707